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Background: This study evaluated safety, pharmacokinetics, and clinical activity of intravenous and oral rucaparib, a poly(ADP-
ribose) polymerase inhibitor, combined with chemotherapy in patients with advanced solid tumours.
Methods: Initially, patients received escalating doses of intravenous rucaparib combined with carboplatin, carboplatin/paclitaxel, cisplatin/
pemetrexed, or epirubicin/cyclophosphamide. Subsequently, the study was amended to focus on oral rucaparib (once daily, days 1–14)
combined with carboplatin (day 1) in 21-day cycles. Dose-limiting toxicities (DLTs) were assessed in cycle 1 and safety in all cycles.
Results: Eighty-five patients were enrolled (22 breast, 15 ovarian/peritoneal, and 48 other primary cancers), with a median of three
prior therapies (range, 1–7). Neutropenia (27.1%) and thrombocytopenia (18.8%) were the most common grade X3 toxicities
across combinations and were DLTs with the oral rucaparib/carboplatin combination. Maximum tolerated dose for the
combination was 240mg per day oral rucaparib and carboplatin area under the curve 5mgml 1min 1. Oral rucaparib
demonstrated dose-proportional kinetics, a long half-life (E17 h), and good bioavailability (36%). Pharmacokinetics were
unchanged by carboplatin coadministration. The rucaparib/carboplatin combination had radiologic antitumour activity, primarily
in BRCA1- or BRCA2-mutated breast and ovarian/peritoneal cancers.
Conclusions: Oral rucaparib can be safely combined with a clinically relevant dose of carboplatin in patients with advanced solid
tumours (Trial registration ID: NCT01009190).
The poly (ADP-ribose) polymerase (PARP) family includes
enzymes that are involved in the repair of single-strand breaks, a
common type of DNA damage, thus preventing the formation of
DNA double-strand breaks (Schreiber et al, 2006). The DNA
double-strand breaks can be repaired by a separate process known
as homologous recombination, mediated by BRCA1 and BRCA2
*Correspondence: Dr R Plummer; E-mail: Ruth.Plummer@newcastle.ac.uk
Received 28 July 2016; revised 14 December 2016; accepted 20 January 2017
r The Author(s) named above
FULL PAPER
Keywords: rucaparib; carboplatin; PARP inhibitor; pharmacokinetics and pharmacodynamics; breast cancer;
ovarian cancer; pancreatic cancer; BRCA1, BRCA2
British Journal of Cancer (2017), 1–9 | doi: 10.1038/bjc.2017.36
Published by Springer Nature on behalf of Cancer Research UK. 1Advance Online Publication: 21 February 2017
(Moynahan et al, 1999, 2001; Venkitaraman, 2002). Tumours
harbouring a BRCA mutation or other defect in homologous
recombination repair are sensitive to PARP inhibitors, because
cells accumulate unrepaired single-strand breaks that are converted
to double-strand breaks that cannot be repaired and therefore
result in cell death (Bryant et al, 2005; Farmer et al, 2005; Helleday
et al, 2007, 2008; Ashworth, 2008). Furthermore, studies have
demonstrated that PARP inhibition can interfere with the
alternative nonhomologous end-joining DNA repair pathway that
is upregulated in homologous recombination-deficient cells
(Helleday, 2011; Ceccaldi et al, 2015; Konstantinopoulos et al,
2015; Mateos-Gomez et al, 2015). The PARP inhibitors can also
result in trapping of PARP-1 and PARP-2 at the site of the DNA
break, resulting in obstructed replication forks that require
functional homologous recombination for repair (Helleday, 2011;
Murai et al, 2012; O’Connor, 2015).
Consistent with the role of PARPs in DNA repair, inhibiting
PARP has been shown to increase the potency of DNA-damaging
agents, such as chemotherapy and radiotherapy (Calabrese et al,
2004; Donawho et al, 2007; Thomas et al, 2007; Ihnen et al, 2013).
Preclinical data suggest that a PARP inhibitor in combination with
carboplatin or cisplatin has enhanced efficacy over either agent
individually in BRCA-mutated tumours (Evers et al, 2008;
Drew et al, 2011; Clark et al, 2012). The synergistic effect
of these combinations may be the result of an increase in DNA
damage (e.g., intrastrand crosslinks) induced by platinum-based
chemotherapies that requires repair through PARP-dependent
pathways.
Rucaparib (formerly known as AG-014699 and PF-01367338) is
a potent small-molecule inhibitor of PARP-1, PARP-2, and PARP-
3 that is being developed for the treatment of ovarian cancer and
other tumour types associated with homologous recombination
deficiency (HRD), including BRCA1 and BRCA2 mutations
(Thomas et al, 2007; Drew et al, 2011; Swisher et al, 2017). In a
phase II study in patients with advanced ovarian or breast cancer
associated with a germline BRCA1/2 mutation, continuous dosing
of single-agent oral rucaparib led to a higher rate of response than
intermittent intravenous (i.v.) dosing (response rate, 18% vs 2%)
(Drew et al, 2016). A subsequent phase I–II dose-escalation study
established the recommended phase II dose of single-agent oral
rucaparib as 600mg twice daily (Kristeleit et al, 2014) and
demonstrated the clinical activity and manageable safety profile of
rucaparib in patients with advanced solid tumours, including
BRCA-mutated ovarian and breast cancers (Kristeleit et al, 2014;
Shapira-Frommer et al, 2015). In phase I and II studies, the
combination of i.v. rucaparib and the DNA-alkylating agent
temozolomide was active in patients with advanced solid tumours
and resulted in increased activity compared with historical data of
single-agent temozolomide in patients with metastatic melanoma
(Plummer et al, 2008, 2013).
This phase I dose-escalation study evaluated rucaparib in
combination with several standard chemotherapeutic regimens in
patients with advanced solid tumours, independent of BRCA
status. The study initially explored an i.v. formulation of rucaparib;
however, during the conduct of this study, an oral formulation of
rucaparib was developed that could be administered for a longer
duration, and the study was amended to evaluate the oral
bioavailability of this new formulation. Once bioavailability was
established, the study was amended to evaluate oral rucaparib in
combination with carboplatin. Here, we report final results from all
patients enrolled in the study, with a focus on those who received
oral rucaparib in combination with carboplatin.
MATERIALS AND METHODS
Study design. This study was an open-label, multicentre, dose-
escalating phase I study of rucaparib administered in combination
with one of four different standard chemotherapeutic regimens
(NCT01009190). Eligible patients X18 years of age had a
histologically or cytologically confirmed advanced solid tumour,
an Eastern Cooperative Oncology Group (ECOG) Performance
Status of 0 or 1, life expectancy of X12 weeks, and adequate bone
marrow, liver, and renal function. All BRCA testing was done
locally and was not verified by the sponsor. The primary objective
was to assess safety and tolerability and estimate the maximum
tolerated dose (MTD) and/or select the recommended phase II
dose of rucaparib in combination with chemotherapy. Secondary
objectives were to characterise the pharmacokinetics (PK) and
assess the antitumour activity of rucaparib when combined with
chemotherapy.
The study was approved by the Research Ethics Committee for
all participating institutions and conducted in accordance with the
Declaration of Helsinki and the Good Clinical Practice Guidelines
of the International Conference on Harmonisation. Patients gave
written informed consent before undergoing any study-related
procedures.
Patients with advanced solid tumours
N=85
Arm A
i.v. rucaparib +
carboplatin
n=18
Dose cohorts
12 mg/AUC4
(n=3)
12 mg/AUC5
(n=3)
18 mg/AUC5
(n=6)
24 mg/AUC5
(n=6)
Arm B
i.v. rucaparib +
paclitaxel + carboplatin
n=13
Dose cohorts
12 mg/140 mg m–2/AUC4
(n=3)
12 mg/175 mg m–2/AUC5
(n=6)
18 mg/175 mg m–2/AUC5
(n=4)
Arm C
i.v. rucaparib +
pemetrexed + cisplatin
n=16
Dose cohorts
12 mg/400 mg m–2/60 mg m–2
(n=3)
12 mg/500 mg m–2/75 mg m–2
(n=6)
18 mg/500 mg m–2/75 mg m–2
(n=4)
24 mg/500 mg m–2/75 mg m–2
(n=3)
Arm D
i.v. rucaparib + epirubicin +
cyclophosphamide
n=5
Dose cohorts
12 mg/30 mg m–2/300 mg m–2
(n=5)
Arm A (Oral)
Oral rucaparib +
carboplatin
n=33
Dose cohorts
80 mg/AUC3 (n=4)
120 mg/AUC3 (n=4)
180 mg/AUC3 (n=3)
240 mg/AUC3 (n=3)
360 mg/AUC3 (n=3)
360 mg/AUC4 (n=3)
360 mg/AUC5 (n=6)
240 mg/AUC5 (n=7)
Figure 1. Study treatment arms.
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Treatments. Patients received escalating doses of i.v. rucaparib
(days 1–3) with standard doses of chemotherapeutic regimens.
Initial starting doses for each chemotherapy were as follows:
arm A, rucaparib (24mg)þ carboplatin (area under the curve
4mgminml 1 (AUC4)); arm B, rucaparib (24mg)þ carboplatin
(AUC4)þ paclitaxel (140mgm 2); arm C, rucaparib (24mg)þ
cisplatin (60mgm 2)þ pemetrexed (400mgm 2); and arm D,
rucaparib (12mg)þ epirubicin (30mgm 2)þ cyclophosphamide
(300mgm 2) (Figure 1). Initially, patients received chemotherapy
(day 1) and i.v. rucaparib (days 1–3) in 21-day treatment cycles.
However, during the conduct of the study, an oral formulation of
rucaparib was developed and introduced under a protocol
amendment, with an additional secondary objective to determine
its absolute oral bioavailability. Subsequently, the i.v. rucaparib
arms were discontinued and three of the chemotherapy arms (B, C,
and D) were closed to further enrolment. Thereafter, all enrolled
patients received oral rucaparib in combination with i.v. carbo-
platin (arm A, oral rucaparib) (Figure 1).
Treatment with rucaparib in combination with chemotherapy
was continued until progression, unacceptable toxicity, patient’s
withdrawal of consent, or as deemed appropriate by the judgement
of the treating physician (whichever came first).
Oral rucaparib in combination with carboplatin. Patients
received lead-in doses of i.v. and oral rucaparib on days  10
and  5, respectively, followed by carboplatin (AUC3, 4, or 5) on
day 1 and oral rucaparib on days 1–14 of every 21-day treatment
cycle. The i.v. lead-in dose of rucaparib was discontinued once
sufficient bioavailability data for oral rucaparib were available. The
starting dose of 80mg oral rucaparib was based on the safety
established with up to 24mgm 2 i.v. rucaparib in combination
with chemotherapy and an oral bioavailability of 36%. The
protocol prespecified dose cohorts of 80, 120, and 180mg oral
rucaparib, after which rucaparib was to be escalated in 50%
increments. Additional doses of 240 and 360mg were subsequently
evaluated. Similarly, carboplatin dosing began at AUC3, with a
plan to escalate to AUC5 once the MTD of rucaparib was
established; however, escalation was modified to evaluate AUC4
carboplatin before escalating to AUC5. Patients discontinuing
carboplatin could continue to receive oral rucaparib.
Safety and efficacy assessments. Safety assessments included
collection of adverse events (AEs) and serious AEs (defined by
National Cancer Institute Common Terminology Criteria for
Adverse Events version 3.0; Pedersen et al, 2013), as well as vital
signs, physical examination, 12-lead electrocardiogram, laboratory
assessments, and verification of concurrent medications. Safety
variables and demographic data were presented descriptively.
The safety analysis set included all enrolled patients who started
treatment.
Dose-limiting toxicities (DLTs) were defined as any of the
following occurring during cycle 1: grade 4 neutropenia lastingX7
days; febrile neutropenia; grade 3 thrombocytopenia lasting X7
days with bleeding or grade 4 thrombocytopenia lasting 43 days;
grade X3 toxicity despite the use of adequate/maximal medical
interventions and/or prophylaxis as dictated by local institutional
clinical practices or the judgement of the investigator; grade 2
neurotoxicity that did not recover to grade p1 within 2 weeks of
planned dose; toxicities that resulted in a delay of 414 days in
initiation of cycle 2 dosing; or toxicities that resulted in failure to
deliver X80% of the assigned oral rucaparib doses.
Initially, at least three patients were treated at each dose level. If
no DLT was observed, the dose was escalated for the next cohort of
three patients. If a DLT was observed in one of the three patients,
three additional patients were enrolled and treated at the same dose
level. If no further DLT was observed, the next dose level was
opened. Dose escalation continued until DLTs were observed in at
least two of the three to six patients treated at that dose level; this
dose was then considered above the MTD and further dose
escalations were stopped. When a dose was concluded to be above
the MTD, the preceding lower dose was declared the MTD, but
only if six patients had already been treated at this lower dose.
Otherwise, three additional patients were treated at this lower dose,
and if none or one of those patients had a DLT, this lower dose was
declared the MTD.
All patients who received at least one dose of study medication
were evaluable for toxicity. Patients were considered nonevaluable
for DLT assessments if they missed the rucaparib lead-in doses,
had administration of o80% of the planned cycle 1 doses of
rucaparib, and/or had administration of o80% of the planned
cycle 1 doses of chemotherapy for that dose level (provided that the
reduction did not result from toxicity).
Antitumour activity was assessed by the investigators according
to Response Evaluation Criteria in Solid Tumor version 1.1
(RECIST) (Eisenhauer et al, 2009) through radiological tumour
assessments performed every two cycles and/or at the end of
treatment, whichever occurred first.
Pharmacokinetics. On cycle 1 days  10,  5, 1, and 14, plasma
samples were obtained from all patients before rucaparib dosing
and at 15 and 30min, and at 1, 1.5, 2.5, 4, 6, 10, and 24 h after the
start of the rucaparib administration (i.v. infusion (day  10) or
oral (days  5, 1, and 14)). On cycle 1 days  10 and  5, samples
were also obtained 48 h after the start of rucaparib administration.
Rucaparib concentration was determined using liquid chromato-
graphy with tandem mass spectrometry. The PK assay was
validated by York Bioanalytical Solutions (York, UK) in accor-
dance with the US Food and Drug Administration’s Bioanalytical
Method Validation Guidance for Industry and Crystal City III
Conference (US Food and Drug Administration, 2001;
Viswanathan et al, 2007; Fast et al, 2009). The PK concentration
analysis population was defined as all treated patients who had at
least one concentration measurement in at least one treatment
period (cycle 1). The PK parameter analysis population was
defined as all treated patients who had at least one of the PK
parameters of interest in at least one treatment period (cycle 1).
Standard plasma PK parameters for rucaparib were estimated
using noncompartmental methods and included: maximum
plasma drug concentration (Cmax); area under the plasma concen-
tration time curve from time 0 to the last sampling time with
measurable values (AUC0–t) and from time 0 to 24 h (AUC0–24);
and half-life (t1/2). Plasma clearance or apparent plasma clearance
and steady-state volume of distribution were calculated for
rucaparib. The oral bioavailability of rucaparib was calculated as
the ratio of dose-normalised AUC0–t or AUCinf (data permitting)
determined using oral rucaparib PK data collected on cycle 1 day
 5 to that determined using the i.v. PK data collected on cycle 1
day  10. Pharmacokinetic parameters were summarised with the
geometric mean and the coefficient of variation (CV). The ratio
of Cmax and AUC0–24 of rucaparib administered in combination
with chemotherapies to those of rucaparib alone was calculated
and summarised, with mean and CV% to evaluate the effect
of chemotherapies on the PK of rucaparib for both the i.v. dose
(day  10) and oral dose (day  5). Additional PK parameters
examined and analyses performed are described in the
Supplementary Methods.
RESULTS
Patients and treatments. Eighty-five patients were enrolled at
seven sites in the United Kingdom and France (Table 1). Median
age was 55 years (range, 20–76 years), approximately two-thirds of
patients were female, and all had an ECOG Performance Status of
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0 or 1. Of the 85 patients, 22 (25.9%) had breast cancer, 15 (17.6%)
had ovarian/peritoneal cancer, 8 (9.4%) had lung cancer, 4 (4.7%)
each had pancreatic or rectal cancer, 31 (36.5%) had other primary
cancers, and 1 (1.2%) patient had a carcinoma of unknown
primary origin. The BRCA test results were unavailable for most
patients (78.8% and 81.2% of patients did not undergo BRCA1 or
BRCA2 testing, respectively). The median number of prior
anticancer therapies was three (range, 1–7).
All patients had discontinued the study as of 2 April 2014. The
median number of cycles initiated was 5 (range, 1–7) in arm A (i.v.
rucaparib; n¼ 18), 4 (range, 1–31) in arm A (oral rucaparib; n¼ 33),
4 (range, 1–6) in arm B (n¼ 13), 4 (range, 1–7) in arm C (n¼ 16),
and 1 (range, 1–4) in arm D (n¼ 5). Eight of 18 (44.4%) patients
from arm A (i.v. rucaparib) and 17 of 33 (51.5%) patients from arm A
(oral rucaparib) had one or more delays (X1 week) between
treatment cycles. These occurred between cycles 1 and 2 in 1 (5.6%)
patient in arm A (i.v. rucaparib) and 9 (27.3%) patients in arm A (oral
rucaparib). Four of 18 (22.2%) patients from arm A (i.v. rucaparib)
had a dose reduction of carboplatin; 8 of 33 (24.2%) patients from
arm A (oral rucaparib) had a dose reduction, including 6 (21.2%) of
carboplatin, 1 (3.0%) of rucaparib, and 1 (3.0%) of both drugs. Across
all cohorts, 76 (89.4%) discontinued treatment with the following as
the primary reason: objective progression or relapse (42 patients,
55.3%), AE (14 patients, 18.4%), global deterioration of health status
(8 patients, 10.5%), no longer willing to participate in the study
(5 patients, 6.6%), and other (7 patients, 9.2%). Specifically, in arm A
(oral rucaparib; n¼ 33) patients discontinued treatment primarily
because of objective progression or relapse (18 patients, 54.5%), global
deterioration of health status (5 patients, 15.2%), AE (3 patients,
9.1%), no longer willing to participate in the study (2 patients, 6.1%),
and other (5 patients, 15.2%).
Dose-limiting toxicity and maximum tolerated dose. In arm A
(oral rucaparib), no patients experienced a DLT at doses up to
360mg rucaparib in combination with AUC4 carboplatin. The first
three patients who received 360mg rucaparib in combination with
AUC5 carboplatin experienced dose interruptions associated with
neutropenia, although these were grade p3 and did not meet the
protocol-specified definition of a DLT. Therefore, a decision was
made to enrol an additional three patients to further evaluate the
safety and tolerability of this dose combination. Dose-limiting
toxicities of grade 4 thrombocytopenia and grade 4 neutropenia
were observed in the first two patients treated, and thus the
third additional patient was not enrolled. The rucaparib dose was
deescalated to 240mg and three patients were treated. One patient
experienced a DLT (grade 4 thrombocytopenia), and thus an
additional three patients were enrolled. None of these three
additional patients had a DLT. Therefore, AUC5 carboplatin and
240mg once daily (q.d.) oral rucaparib was declared the MTD.
Dose-limiting toxicities were also reported in one patient in arm
B who was receiving 36mg rucaparib, 306mg paclitaxel, and
610mg carboplatin (grade 3 diarrhoea and grade 3 nausea) and in
one patient in arm C who was receiving 12mg rucaparib, 900mg
pemetrexed, and 135mg cisplatin (grade 3 fatigue, grade 4
leukopenia, and grade 4 neutropenia). Because of a decision to
discontinue recruitment to the i.v. rucaparib arms during the
study, no MTD was determined for arms A (i.v. rucaparib),
B, C, and D that evaluated i.v. rucaparib in combination with
chemotherapy.
Table 1. Patient demographics and disease characteristics
Variable
Arm A, i.v.
rucaparibþ
carboplatin
(n¼18)
Arm B, i.v.
rucaparibþ
carboplatin/
paclitaxel
(n¼13)
Arm C, i.v.
rucaparibþ
cisplatin/
pemetrexed
(n¼16)
Arm D, i.v.
rucaparibþ
epirubicin/
cyclophosphamide
(n¼5)
Arm A,
oral rucaparibþ
carboplatin
(n¼33)
All patients
(N¼85)
Median age (range), years 51.5 (23–68) 61.0 (39–69) 50.5 (32–68) 41.0 (32–53) 61.0 (20–76) 55.0 (20–76)
Gender, n (%)
Female 11 (61.1) 7 (53.8) 10 (62.5) 4 (80.0) 23 (69.7) 55 (64.7)
Male 7 (38.9) 6 (46.2) 6 (37.5) 1 (20.0) 10 (30.3) 30 (35.3)
Race, n (%)
Asian 0 0 1 (6.3) 0 0 1 (1.2)
Black 1 (5.6) 1 (7.7) 0 0 0 2 (2.4)
White 17 (94.4) 12 (92.3) 15 (93.8) 5 (100.0) 33 (100.0) 82 (96.5)
ECOG PS, n (%)
0 7 (38.9) 6 (46.2) 6 (37.5) 5 (100.0) 16 (48.5) 40 (47.1)
1 11 (61.1) 7 (53.8) 10 (62.5) 0 17 (51.5) 45 (52.9)
Primary cancer diagnosis, n (%)
Breast 7 (38.9) 1 (7.7) 4 (25.0) 4 (80.0) 6 (18.2) 22 (25.9)
Ovarian/peritoneal 2 (11.1) 1 (7.7) 2 (12.5) 0 10 (30.3) 15 (17.6)
Lung 1 (5.6) 2 (15.4) 1 (6.3) 1 (20.0) 3 (9.1) 8 (9.4)
Pancreas 0 0 2 (12.5) 0 2 (6.1) 4 (4.7)
Rectal 3 (16.7) 0 0 0 1 (3.0) 4 (4.7)
Unknown primary 1 (5.6) 0 0 0 0 1 (1.2)
Othera 4 (22.2) 9 (69.2) 7 (43.8) 0 11 (33.3) 31 (36.5)
BRCA1 test results, n (%)
Positive 2 (11.1) 1 (7.7) 2 (12.5) 0 2 (6.1) 7 (8.2)
Negative 3 (16.7) 0 0 3 (60.0) 3 (9.1) 9 (10.6)
Unknown 0 0 0 0 2 (6.1) 2 (2.4)
Not tested 13 (72.2) 12 (92.3) 14 (87.5) 2 (40.0) 26 (78.8) 67 (78.8)
BRCA2 test results, n (%)
Positive 2 (11.1) 0 0 0 1 (3.0) 3 (3.5)
Negative 1 (5.6) 1 (7.7) 2 (12.5) 3 (60.0) 4 (12.1) 11 (12.9)
Unknown 1 (5.6) 0 0 0 1 (3.0) 2 (2.4)
Not tested 14 (77.8) 12 (92.3) 14 (87.5) 2 (40.0) 27 (81.8) 69 (81.2)
Median no. of prior anticancer
therapies (min, max)
2.5 (1, 5) 2.0 (1, 6) 2.0 (1, 6) 3.0 (2, 5) 3.0 (1, 7) 3.0 (1, 7)
Abbreviations: ECOG PS¼Eastern Cooperative Oncology Group Performance Status; i.v.¼ intravenous.
aPrimary cancer diagnosis sites, including: appendix (n¼ 2), colon (n¼ 2), endometrium (n¼ 2), pleura (n¼ 2), stomach (n¼ 2), abdomen (n¼ 1), adrenal glands (n¼ 1), back (n¼ 1), bladder
(n¼ 1), oesophagus (n¼ 1), ear (n¼ 1), face (n¼ 1), forearm (n¼ 1), gastroesophageal junction (n¼ 1), left leg (n¼ 1), liver (n¼ 2), prostate (n¼ 1), shoulder (n¼ 1), skin (n¼ 1), testes (n¼ 1), and
not available (n¼ 5).
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Adverse events. All except one patient experienced an AE during the
study. Adverse events occurring in420% of patients in any treatment
group are summarised in Table 2. Across the treatment arms, AEs
were generally grade 1 or 2 in severity. The most common AEs (with
X30% incidence in all patients) across groups were gastrointestinal
events (i.e., nausea, constipation, vomiting, and diarrhoea), fatigue,
and events related to myelosuppression (i.e., anaemia, neutropenia,
and thrombocytopenia). Grade X3 AEs were reported in 64 of
85 patients (75.3%), the most frequent of which were neutropenia
(23 patients, 27.1%), thrombocytopenia (16 patients, 18.8%), fatigue
(11 patients, 12.9%), anaemia (10 patients, 11.8%), nausea (6 patients,
7.1%), and the following in 5 patients (5.9%) each: vomiting,
g-glutamyltransferase increased, and dyspnoea. Myelosuppression
was managed through transfusion or supportive medication when
necessary; one patient (in arm C) received granulocyte colony-
stimulating factor in response to grade 2 neutropenia. Treatment-
related AEs, as assessed by investigators, were reported in 94.1% of
patients (Supplementary Table S1).
Across treatment arms, 22 patients (25.9%) discontinued treatment
because of AEs that included neutropenia (3 patients, 3.5%), thrombo-
cytopenia (2 patients, 2.4%), and platinum hypersensitivity (2 patients,
2.4%). While on study, 6 patients (7.1%) died of disease progression
that was assessed as unrelated to study drug.
Pharmacokinetics. Rucaparib exposure increased approximately
dose proportionally when given orally or intravenously (Supple-
mentary Tables S2–S5). On study day 14, the steady-state AUC0–24
increased by an average of 61%, with no change in t1/2 compared
with a single dose. Regardless of the administration route, the dose-
independent t1/2 was E17 h as observed in patients from arm A
(oral rucaparib) who received 27mg i.v. rucaparib on day  10
and 80mg oral rucaparib on day  5 (Figure 2). Rucaparib
demonstrated good absorption, with a dose-independent mean
oral bioavailability of 36% in the fasted state. Rucaparib oral PK
was not affected by coadministration of AUC3 to AUC5
carboplatin (Table 3). No apparent impact on i.v. rucaparib PK
was observed with coadministration of carboplatinþ paclitaxel,
cisplatinþ pemetrexed, or epirubicinþ cyclophosphamide (Table 3).
Tumour response. Tumour response data were available for 77 of
85 patients. Across all cohorts, 1 patient (1.2%) with breast cancer
achieved a confirmed complete response (CR) and 9 patients
(10.6%) achieved a partial response (PR) that was confirmed in 7
patients (Table 4). Forty-three patients (50.6%) achieved stable
disease (SD). Among patients with available data, across all
cohorts, the disease control rate (CR, PR, or SD for X12 weeks)
was 68.8%. Three of 33 patients (9.1%) receiving oral rucaparib in
Table 2. Treatment-emergent adverse events of any grade reported in 420% of patients in any treatment group
Arm A, oral
rucaparibþ carboplatin
(n¼33) n (%)
Event
Arm A, i.v.
rucaparibþ
carboplatin
(n¼18),
n (%)
Arm B, i.v.
rucaparibþ
carboplatin/
paclitaxel
(n¼13), n (%)
Arm C, i.v.
rucaparibþ
cisplatin/
pemetrexed
(n¼16), n (%)
Arm D, i.v.
rucaparibþ
epirubicin/
cyclophosphamide
(n¼5), n (%)
Any
grade
Grade
X3
All patients
(N¼85), n (%)
Nausea 14 (77.8) 7 (53.8) 10 (62.5) 4 (80.0) 23 (69.7) 4 (12.1) 58 (68.2)
Fatigue 14 (77.8) 4 (30.8) 14 (87.5) 1 (20.0) 20 (60.6) 2 (6.1) 53 (62.4)
Constipation 10 (55.6) 5 (38.5) 9 (56.3) 1 (20.0) 17 (51.5) 1 (3.0) 42 (49.4)
Vomiting 8 (44.4) 5 (38.5) 8 (50.0) 1 (20.0) 16 (48.5) 4 (12.1) 38 (44.7)
Anaemia 6 (33.3) 2 (15.4) 8 (50.0) 0 18 (54.5) 4 (12.1) 34 (40.0)
Neutropenia 8 (44.4) 7 (53.8) 8 (50.0) 0 11 (33.3) 7 (21.2) 34 (40.0)
Diarrhoea 7 (38.9) 5 (38.5) 9 (56.3) 1 (20.0) 11 (33.3) 1 (3.0) 33 (38.8)
Thrombocytopenia 6 (33.3) 3 (23.1) 5 (31.3) 0 15 (45.5) 9 (27.3) 29 (34.1)
Decreased appetite 5 (27.8) 0 4 (25.0) 2 (40.0) 12 (36.4) 0 23 (27.1)
Abdominal pain 3 (16.7) 3 (23.1) 1 (6.3) 0 12 (36.4) 2 (6.1) 19 (22.4)
Headache 5 (27.8) 2 (15.4) 4 (25.0) 1 (20.0) 7 (21.2) 0 19 (22.4)
Dyspnoea 5 (27.8) 1 (7.7) 5 (31.3) 1 (20.0) 7 (21.2) 2 (6.1) 19 (22.4)
Cough 2 (11.1) 0 6 (37.5) 0 8 (24.2) 0 16 (18.8)
Lethargy 1 (5.6) 6 (46.2) 1 (6.3) 0 7 (21.2) 0 15 (17.6)
Back pain 3 (16.7) 1 (7.7) 1 (6.3) 0 10 (30.3) 1 (3.0) 15 (17.6)
Alopecia 2 (11.1) 10 (76.9) 2 (12.5) 0 1 (3.0) 0 15 (17.6)
Stomatitis 4 (22.2) 6 (46.2) 1 (6.3) 1 (20.0) 2 (6.1) 0 14 (16.5)
Pyrexia 3 (16.7) 1 (7.7) 3 (18.8) 2 (40.0) 5 (15.2) 0 14 (16.5)
Dyspepsia 2 (11.1) 2 (15.4) 4 (25.0) 0 4 (12.1) 0 12 (14.1)
Oral candidiasis 1 (5.6) 2 (15.4) 6 (37.5) 1 (20.0) 1 (3.0) 0 11 (12.9)
Arthralgia 2 (11.1) 3 (23.1) 4 (25.0) 0 2 (6.1) 0 11 (12.9)
Neuropathy peripheral 0 7 (53.8) 3 (18.8) 0 0 0 10 (11.8)
Insomnia 1 (5.6) 0 5 (31.3) 0 3 (9.1) 0 9 (10.6)
Abdominal pain upper 2 (11.1) 1 (7.7) 0 2 (40.0) 3 (9.1) 1 (3.0) 8 (9.4)
Epistaxis 1 (5.6) 0 5 (31.3) 0 0 0 6 (7.1)
Tachycardia 2 (11.1) 0 4 (25.0) 0 0 0 6 (7.1)
Asthenia 0 0 0 4 (80.0) 0 0 4 (4.7)
Influenza-like illness 0 0 4 (25.0) 0 0 0 4 (4.7)
Abbreviation: i.v.¼ intravenous.
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combination with carboplatin had a confirmed PR. These included
a patient with ovarian/peritoneal cancer (BRCA1 mutation, BRCA2
wild type) who had a PR for 7 months, a second patient with
ovarian/peritoneal cancer (BRCA1 and BRCA2 wild type) who had
a PR for 5 months, and a patient with breast cancer (BRCA1
mutation, BRCA2 not tested) who had a PR for 3 months. None of
these patients had received prior PARP inhibitor therapy.
DISCUSSION
This phase I study demonstrated that oral rucaparib can be safely
combined with a clinically relevant dose of carboplatin in patients
with an advanced solid tumour. The MTD and recommended dose
for the combination is 240mg q.d. rucaparib on days 1–14 with
AUC5 carboplatin on day 1 in 21-day cycles.
Oral rucaparib demonstrated dose-proportional kinetics and a
long t1/2 (E17 h) with good oral bioavailability (36%) independent
of dose, all of which are desirable characteristics for an oral agent.
These PK findings with oral rucaparib are consistent with results
from the phase I portion of an ongoing phase I–II study evaluating
single-agent oral rucaparib in patients with advanced solid
tumours (Kristeleit et al, 2014). Pharmacokinetic exposure to oral
rucaparib was not changed by carboplatin coadministration.
When used in combination with AUC5 carboplatin, the i.v.
rucaparib doses of 12, 18, and 24mg evaluated were approxi-
mately equivalent to oral rucaparib doses of 33, 50, and 67mg,
respectively, representing 14%, 21%, and 28% of the MTD of
240mg oral rucaparib.
As anticipated with the concurrent administration of chemo-
therapeutic agents with rucaparib, myelosuppression (anaemia,
neutropenia, and thrombocytopenia) was commonly reported.
Myelosuppression is a known toxicity associated with a high
dose of PARP inhibitors and is also often observed with many
chemotherapy regimens (Sandhu et al, 2013; Plummer et al, 2014;
Kaufman et al, 2015; Shapira-Frommer et al, 2015). In our study,
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Figure 2. Plasma rucaparib concentration–time profile following i.v. or oral administration. Graph shows the geometric mean plasma
concentration of rucaparib in patients in arm A (oral rucaparib) (n¼ 4) who received i.v. and oral doses on days  10 and 5, respectively.
Table 3. Effect of carboplatin on oral rucaparib PK parameters and of chemotherapy on i.v. rucaparib PK parameters
Ratio of rucaparib PK parameters,a mean (CV%)
Cmax AUC0–24
Oral rucaparib
Carboplatin dose
AUC3 (n¼ 15) 1.25 (46) 1.27 (37)
AUC4 (n¼ 3) 0.928 (24) 1.15 (51)
AUC5 (n¼ 11) 1.14 (59) 1.00 (48)
Overall (n¼29) 1.18 (49) 1.15 (87)
Ratio of rucaparib PK parameters,b mean (CV%)
Cmax AUC0–24
i.v. rucaparib
Chemotherapy
Carboplatin (n¼6) 1.03 (16) 1.02 (15)
Carboplatinþpaclitaxel (n¼ 6) 0.917 (16) 0.86 (8)
Cisplatinþpemetrexed (n¼8) 0.853 (42) 0.959 (20)
Epirubicinþ cyclophosphamide (n¼5) 0.968 (29) 0.916 (34)
Abbreviations: AUC¼ area under the concentration time curve; AUC0–24¼AUC for time 0 to 24 h; Cmax¼maximum plasma drug concentration; CV¼ coefficient of variation; i.v.¼ intravenous;
PK¼pharmacokinetic.
aRatio of rucaparib PK parameter on day 1/day  5 with single oral dose of rucaparib (80, 120, 180, 240, and 360mg) on day  5 and single oral dose of rucaparib (80, 120, 180, 240, and 360mg)
followed 1.5 h later with 30min i.v. infusion of carboplatin (AUC3, AUC4, or AUC5) on day 1.
bRatio of rucaparib PK parameter on day 1/day  10 with i.v. dose of rucaparib (12, 18, or 24mg) on day  10 and i.v. rucaparib plus i.v. chemotherapy on day 1; for AUC4, n¼ 2 for AUC ratio;
for overall, n¼ 28 for AUC ratio.
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thrombocytopenia and neutropenia were DLTs and also the most
common severe toxicities reported across all treatment arms.
Myelosuppression was also observed in 54% of patients treated with
the combination of i.v. rucaparib and temozolomide in another study
(Plummer et al, 2013). The combination of the PARP inhibitor
olaparib with chemotherapy, including carboplatin, has also been
associated with substantial hematologic toxicity in phase I studies of
patients with an advanced solid tumour (Khan et al, 2011; Rajan et al,
2012; Samol et al, 2012; Dent et al, 2013; Lee et al, 2014a).
Rucaparib exhibited clinical activity in combination with
chemotherapy in this study of heavily pretreated patients with
advanced malignancies. More than two-thirds of all patients in the
study had stable disease or better, and this is notable because
patients were not preselected for HRD (only 10 of 85 patients were
known to harbour a BRCA mutation). Of patients who received
oral rucaparib and carboplatin, 63.6% achieved disease control
for X12 weeks, and PRs were reported in 3 patients with ovarian
or breast cancer, 2 of whom had a known BRCA mutation.
The benefits of inhibiting PARP in BRCA-mutated ovarian or
breast cancer are well documented (Fong et al, 2009; Audeh et al,
2010; Tutt et al, 2010; Kaye et al, 2012; Sandhu et al, 2013; Lee et al,
2014b). As a single agent, oral rucaparib has demonstrated
activity against BRCA-mutated ovarian and breast cancer
(Shapira-Frommer et al, 2015; Drew et al, 2016; Swisher et al,
2017) and is currently being evaluated in phase III studies as both
maintenance and treatment therapy for patients with relapsed,
high-grade ovarian cancer (ARIEL3 (NCT01968213) and ARIEL4
(NCT02855944)).
When used in combination with carboplatin, the dose of rucaparib
(240mg q.d.) is lower than the MTD of single-agent rucaparib
(600mg twice daily). The lower dose of rucaparib in the combination
fits with prior studies demonstrating a synergistic effect with
combinations of PARP inhibitors and DNA-damaging agents at
lower doses (Calabrese et al, 2004; Donawho et al, 2007; Thomas
et al, 2007; Ihnen et al, 2013). Given that platinum-based
chemotherapies increase the burden of DNA damage in cells, the
addition of PARP inhibition increases the cytotoxicity of these agents
by preventing repair of damaged DNA. Although PARP inhibitors in
the single-agent setting have demonstrated benefits in DNA-repair-
deficient cancers (e.g., BRCA-mutated ovarian cancer), combinations
such as rucaparib and carboplatin may be useful in a wider
population, including in cancers with and without homologous repair
deficiency.
In conclusion, this study demonstrated that oral rucaparib can
be safely combined with a clinically relevant dose of carboplatin;
however, neutropenia and thrombocytopenia were commonly
observed with the rucaparib/carboplatin combination. All patients
who receive rucaparib in combination with carboplatin should be
monitored carefully for myelosuppression. The oral and i.v. PK
profile of rucaparib was not affected by coadministration of the
chemotherapeutic agents that were investigated in this study.
Three heavily pretreated patients who received oral rucaparib and
carboplatin had a clinical response; further work investigating this
combination may be warranted.
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